Suzuki, T., Mizoshita, T., Sugiyama, T., Hirata, Y., Kimura, Y., Suzuki, Y., . . . Sasaki, M. (2019). Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol.
Styl ChicagoSuzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.
Citace podle MLASuzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.